TNFRSF4 and neoplasm: Targeting co-stimulatory molecules, such as the ligand of tumor necrosis factor receptor superfamily member 4 of (OX40) alleviates immunosuppression within the tumor microenvironment by inhibiting the activity of regulatory T cells (Tregs).